Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Acquisition of TopSport: Plug and Play

BETR Entertainment
3:27pm
February 12, 2025
The acquisition of TopSport ticks all the right boxes in our eyes and will give BBT the necessary scale to edge closer to both its market share targets, while achieving profitability. Strategically, the acquisition expands BBT’s market share from ~5% to ~6% and is expected to be >30% EPS accretive to consensus forecasts in FY26–27F (MorgansF: 42% / 32%). BBT remains confident in its execution, viewing this as the first step in a broader M&A strategy over the next 12 months. The transaction includes an upfront payment of $10m (70% cash, 30% scrip), along with deferred earn-out payments and performance-based incentives. As part of the deal, BBT has issued 44.1m new shares through an institutional placement, raising $15m. Completion is expected in April 2025. We reiterate an Add rating. Our target price is $0.47, implying 30% TSR.

2H towing a heavy load

Amotiv
3:27pm
February 12, 2025
AOV reported in line with expectations, delivering 1H25 sales growth of +2% (-3% LFL); EBITA -1%; and flat NPATA. EBITA margins were softer across the board. The group reaffirmed FY25 guidance (revenue and EBITA growth), with various initiatives, business wins and recent investments to contribute to a stronger 2H. Ultimately a resilient, but somewhat uninspiring, 1H25 result. We continue to see value in the name (~11x FY26F PE), but we expect patience will be required as AOV navigates challenging markets (NZ) and realises recent investments (SA).

Indicators continue to firm

IMDEX
3:27pm
February 12, 2025
Following a solid 1H result and material FX tailwinds to start 2H, FY25 numbers now look more than achievable. This means focus should quickly turn to FY26. Though the stock is expensive relative to history (~25x FY25 adjusted PE), if current conditions persist, we think IMD can hold this multiple into FY26. Gold continues to reset all-time highs (>US$2900/oz), copper has bounced (US$4.60/lb), and, most importantly, junior miner raisings have finally established a trend over the past 4 months (in aggregate +80% YoY). This should translate into rising volumes. While we make negligible changes to our FY25 forecasts, we increase FY26-27 adjusted EPS by +4-6%. Our target price increases to $3.20 at 25x FY26 adjusted PE.

A robust 1H25 result

Suncorp Group
3:27pm
February 12, 2025
SUN’s 1H25 group cash earnings (A$860m) were 10% above consensus (A$781m), with the main driver being lower 1H25 hazard claims than expected. Overall we saw this as a strong 1H25 result for SUN, with it being accompanied by significant capital returns as expected, and with FY25 key guidance parameters largely unchanged. We lift our SUN FY25 cash EPS forecasts by 9% on lower claims costs than expected, but reduce FY26F EPS by 3% on a lower buyback level than we envisaged. Our valuation rises to A$22.33 on our earnings changes and valuation roll-forward. With a solid outlook continuing in FY25 and SUN still having ~10% TSR upside on a 12-month view, we maintain our ADD call

Sales up but cash is tight

Next Science
3:27pm
February 12, 2025
NXS has posted a modest increase in sales for FY24. The highlight from the 4Q24 result was the increased contribution from EXPERIENCETM and improved margins. Cash at the end of the period remains tight with management noting a focus on moving to a cashflow positive position.

Tariffs continue to stir caution

BRG Group
3:27pm
February 11, 2025
BRG’s 1H25 result was slightly ahead of expectations, recording revenue (+10%) and NPAT (+16%) growth on the pcp. A solid result, with good top-line growth across key markets (all delivering double-digit constant currency revenue growth), resilient margins (EBIT margin flat yoy), a solid capital position (net cash as of Jan 31, 2025), and continued momentum in new geographies (+36% yoy) and NPD (further launches planned for 2H25). While we view BRG’s FY25 EBIT guidance may prove conservative, we remain cautious given the challenging and rapidly evolving operating environment. We continue to view BRG as a high-quality business; however, its valuation (~3x FY26 PEG) appears to fully reflect its near-term growth trajectory. As a result, we prefer to wait for a more compelling entry point. Hold maintained.

Setting the platform for development

Deep Yellow
3:27pm
February 11, 2025
We recently visited Deep Yellow’s Tumas project in Namibia as Final Investment Decision approaches in March 2025. Early works including road/haulage infrastructure are well underway and progressing well after beginning late 2024. Grade control is steaming ahead with 3 RC rigs drilling Tumas 3 on a tight 12.5m x 12.5m spacing. We raise our price target to A$1.73ps (previously A$1.69ps), a function of increased mined inventory, following the December reserve upgrade.

1H soft; Behring solid, Seqirus soft, Vifor strength

CSL Ltd
3:27pm
February 11, 2025
1H results were a bit soft, with FX denting bottom line growth and vaccine sales pulling down top line gains, although constant currency (cc) margins held and OCF was strong. Divisional sales were mixed, with continued strong plasma collections propelling Behring sales (+10%) and Vifor showing surprising strength (+6%), while Seqirus failed to overcome weak immunisations in the US. Notably, Behring GPM expanded above expectations (+170bp, 51.7%), owing to lower cost/litre and numerous other initiatives, with the return to pre-COVID margins (c58%) still targeting FY27/28. FY24 guidance (cc NPATA +10-13%) was reaffirmed, implying a very strong 2H (+19% at mid-point), which looks achievable given Vifor’s growth and pandemic avian influenza contracts for Seqirus, with overall double-digit earnings growth continuing to be expected over the medium term. Our PT moves to A$329.26 on modest earnings changes and FX. Add.

International Spotlight

AstraZeneca PLC
3:27pm
February 11, 2025
AstraZeneca is an Anglo-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. It is science-led and patient-focussed within its four primary therapy areas: Oncology, Biopharmaceuticals, Vaccine and Immune Therapies; and Rare Diseases. AstraZeneca is focussed on the discovery, delivery and commercialisation of prescription medicines.

Phase 3 clinical trial begins and coverage ceases

Tissue Repair
3:27pm
February 11, 2025
TRP has recruited the first patient into its US Phase 3 trial for chronic venous leg ulcers. TRP is also pursuing a medical device application in addition to the traditional drug path which according to management may see an earlier approval. TRP finished with cash of A$14.4m at 2Q25. We are continually reviewing our Healthcare coverage list. At this time we will remove TRP from our Keeping Stock coverage.

News & Insights

Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more
The U.S. and China, through negotiations led by the Chinese Deputy Premier and U.S. Treasury Secretary Scott Bessent, agreed to a 90-day tariff reduction from over 125% to 30% and 10% respectively

US and Chinese actions had led to an unintended embargo of trade between the world’s two largest economies.

In recent days there has been discussion of the temporary “cease fire” in the tariff war between the US and China.

The situation was that both countries had levied tariffs on each other more than 125%. This had led to a mutual embargo of trade between the two world is two largest economies. Then as a result of negotiation between the Deputy Premier of China and US Treasury Secretary Scott Bessent both China and the US agreed to a 90 day pause in “hostilities” where both sides agreed to reduce the US tariff on the China to 30 percent and the Chinese tariff on the US to 10%.

Some suggested that this meant that “China had won” others suggested that the “US had won.” To us this really suggests that both parties were playing in a different game. The was a game in which both sides had won.

To understand why this is the case we must understand a little of the theory of this type of competition. Economists usually use discuss competition in terms of markets where millions of people are involved. In such a case we find a solution by finding the intersection of supply and demand which model the exchange between vast numbers of people.

But here we are ware talking of a competition where only two parties are involved.

When exceedingly small numbers like this are involved, we find the solution to the competition by what is called “Game Theory.”

In this game there are only two players. One is called China, and the other is called the US. Game theory teaches us that are there three different types of games. The first is a zero-sum game. In this game there two sides are competing over a fixed amount of product. Again, this is called " A zero sum game “. Either one party gets a bigger share of the total sum at stake and the other side gets less. This zero-sum game is how most of the Media views the competition between the US and China.

A second form is a decreasing sum game. An example of this is a war. Some of the total amount that is fought over is destroyed in the process. Usually both sides will wind up worse than when they started.

Then there is a third form. This form is called an ‘increasing sum game.’ This is where both sides cooperate so that the total sum in the game grows because of this cooperation. We think that what happened in the US and China negotiation was an increasing sum game.

As Scott Bessent said at the Saudi Investment Forum in Riyadh soon after the agreement was signed, “both sides came with a clear agenda with shared interests and great mutual respect.”

He said, “after the weekend, we now have a mechanism to avoid escalation like we had before. We both agreed to bring the tariff levels down by 115% which I think is very productive because where we were with 145% and 125% was an unintended embargo. That is not healthy for the two largest economies in the world.”

He went on, “when President Trump began the tariff program, we had a plan, we had a process. What we did not have with the Chinese was a mechanism. The Vice Premier and I now call this the ‘Geneva mechanism’”.

Both sides cooperated to make both sides better off. Bessent added “what we do not want, and both sides agreed, is a generalised decoupling between the two largest economies in the world. What we want is the US to decouple in strategic industries, medicine, semiconductors, other strategic areas. As to other countries; we have had very productive discussions with Japan, South Korea, Indonesia, Taiwan, Thailand. Europe may have collective action problems with the French wanting one thing and the Italians wanting a different thing. but I am confident that with Europe, we will arrive at a satisfactory conclusion.

We have a very good framework. I think we can proceed from here.”

What we think we can see here is that the United States and China have cooperated to both become better off. This is what we call an increasing sum game.

They will continue their negotiation using that approach. This will do much to allay the concerns that so many had about the effect of these new tariffs.

Read more